Danaher Corporation vs Entegris Inc — how do they compare? Danaher Corporation trades at $207.35 (market cap $145.83B), while Entegris Inc trades at $160.65 (market cap $22.95B). The key difference: Danaher Corporation is far larger — about 6.4× Entegris Inc's market cap, and Danaher Corporation pays the higher dividend (0.77%). Which is the better fit depends on your goals.
| DHR | ENTG | |
|---|---|---|
Market Cap | $145.83B | $22.95B |
Sector | Health | Technology |
52-Week High | $242.05 | $184.00 |
52-Week Low | $161.91 | $68.80 |
Enterprise Value | $168.04B | $26.16B |
Dividend Yield | 0.77% | 0.27% |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
ENTG trades at $159.66, up 10.71% in 24 hours, reflecting strong momentum driven by Q2 2026 earnings beats and AI-driven semiconductor demand. The stock is near its 52-week high with bullish technical indicators and a consensus price target of $188.67. Revenue growth and margin expansion highlight operational strength, though elevated P/E and P/S ratios signal high valuation expectations.
Outlook is positive with continued earnings growth potential from semiconductor industry tailwinds, but risks include valuation sensitivity and competitive pressures. The stock offers upside to analyst targets but requires monitoring of execution and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →